Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SESEN BIO, INC.

(SESN)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-30 pm EST
0.6100 USD   -3.27%
01/30Sesen Bio Receives Nasdaq Delisting Notice, Plans to Request Hearing
MT
01/30Sesen Bio Receives NASDAQ Delisting Notice
BU
01/30Sesen Bio, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SESEN BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Sesen Bio, Inc. - SESN

09/21/2022 | 08:23pm EST

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sesen Bio, Inc. (NasdaqCM: SESN) (the “Company”) with Carisma Therapeutics Inc., pursuant to which pre-merger Sesen Bio shareholders are expected to own approximately 41.7% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-sesn/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.


ę Business Wire 2022
All news about SESEN BIO, INC.
01/30Sesen Bio Receives Nasdaq Delisting Notice, Plans to Request Hearing
MT
01/30Sesen Bio Receives NASDAQ Delisting Notice
BU
01/30Sesen Bio, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St..
AQ
01/26Bradley L Radoff Issues a Letter to the Boards of Sesen Bio and Carisma Rejecting Their..
CI
01/26Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests o..
BU
01/25Bradley L Radoff Sends a Letter to Sesen Bio Inc
CI
01/25Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their App..
BU
01/19Sesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connecti..
BU
01/05Investor Group Issues Letter to Sesen Bio's Board of Directors Regarding Intent to Vote..
BU
01/05Bradley L. Radoff and Michael Torok Issue Letter to Sesen Bio’s Board of Directors..
CI
More news
Analyst Recommendations on SESEN BIO, INC.
More recommendations
Financials (USD)
Sales 2022 40,0 M - -
Net income 2022 -38,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,21x
Yield 2022 -
Capitalization 124 M 124 M -
Capi. / Sales 2022 3,09x
Capi. / Sales 2023 -
Nbr of Employees 17
Free-Float 92,3%
Chart SESEN BIO, INC.
Duration : Period :
Sesen Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SESEN BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Last Close Price 0,61 $
Average target price 0,60 $
Spread / Average Target -1,64%
EPS Revisions
Managers and Directors
Thomas R. Cannell President, Chief Executive Officer & Director
Monica Forbes Chief Financial Officer & Treasurer
Stephanie Vigue Finance Director
Jay S. Duker Chairman
Glen C. MacDonald Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
SESEN BIO, INC.3.46%124
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.07%79 336
WUXI APPTEC CO., LTD.18.94%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.16.46%27 008